Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com

November 30, 2017 3:00 PM JST

Chordia Therapeutics Raises $~11 million in Series A Financing

Chordia Therapeutics, an oncology focused research and development company launched in Kanagawa, Japan, raises approximately *1.2B Yen ($~11M) Series A financing*

Kanagawa, Japan, November 30, 2017 – Chordia Therapeutics Inc. ("Chordia"), an oncology focused research and development company, today announced that it has received approximately 1.2B Yen ($~11M) in Series A financing to advance its lead asset CDC-like kinase ("CLK") inhibitor towards clinical trials and move forward other preclinical assets. The financing was led by Takeda Pharmaceutical Company Limited ("Takeda") and Kyoto University Innovation Capital ("KYOTO-iCAP"). Mitsubishi UFJ capital and SMBC venture capital also participated in the financing. Chordia will receive other research and development support from Takeda. Chordia has appointed Nenad Grmusa, Head of Global R&D Finance at Takeda, and Hiroyuki Ueno, Ph.D., Principal at KYOTO-iCAP to its board of directors.

Chordia, which entered into an investment agreement with Takeda and a venture capital syndicate on November 21, 2017 will reside at the Health Innovation Park in Shonan. Under the terms of the deal, Takeda and the venture capital syndicate invested in Series A financing. Hiroshi Miyake, Ph.D., representative director of Chordia said, "Our mission is to deliver innovative cancer medicine to patients by combining cutting-edge science from Kyoto University, and our knowledge and expertise in drug discovery. Support from Takeda and leading venture capitalists in Japan enables us to move the CLK program forward to clinical trials as quickly as possible."

Chordia continues to accelerate drug discovery in oncology areas of high unmet medical needs. Miyake said, "CLK is a kinase regulating RNA splicing which is a fundamental biological process for a cell. It was discovered by our collaborator Professor Seishi Ogawa at Kyoto University and other researchers that a significant number of cancer patients possess a mutation in splicing factors, which shows that splicing abnormalities is one of causative events of cancer development. We will explore whether our CLK inhibitor is effective for treating patients with these mutations."
For more details, visit www.chordiatherapeutics.com